BDSX Stock Overview
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.48|
|52 Week High||US$16.40|
|52 Week Low||US$1.31|
|1 Month Change||-4.52%|
|3 Month Change||-53.31%|
|1 Year Change||-89.00%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-88.45%|
Recent News & Updates
|BDSX||US Healthcare||US Market|
Return vs Industry: BDSX underperformed the US Healthcare industry which returned 1.8% over the past year.
Return vs Market: BDSX underperformed the US Market which returned -12.7% over the past year.
|BDSX Average Weekly Movement||17.2%|
|Healthcare Industry Average Movement||10.6%|
|Market Average Movement||7.9%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||3.0%|
Stable Share Price: BDSX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: BDSX's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient’s immune system to establish the patient’s prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test.
Biodesix Fundamentals Summary
|BDSX fundamental statistics|
Is BDSX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BDSX income statement (TTM)|
|Cost of Revenue||US$15.54m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.30|
|Net Profit Margin||-160.88%|
How did BDSX perform over the long term?See historical performance and comparison
Is Biodesix undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BDSX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate BDSX's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: BDSX is unprofitable, so we can't compare its PE Ratio to the US Healthcare industry average.
PE vs Market: BDSX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BDSX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BDSX is overvalued based on its PB Ratio (7.6x) compared to the US Healthcare industry average (2.6x).
How is Biodesix forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BDSX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BDSX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BDSX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BDSX's revenue (22.9% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: BDSX's revenue (22.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BDSX is forecast to be unprofitable in 3 years.
How has Biodesix performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BDSX is currently unprofitable.
Growing Profit Margin: BDSX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BDSX is unprofitable, and losses have increased over the past 5 years at a rate of 15.5% per year.
Accelerating Growth: Unable to compare BDSX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BDSX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (8.8%).
Return on Equity
High ROE: BDSX has a negative Return on Equity (-665.52%), as it is currently unprofitable.
How is Biodesix's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: BDSX's short term assets ($27.2M) do not cover its short term liabilities ($29.8M).
Long Term Liabilities: BDSX's short term assets ($27.2M) exceed its long term liabilities ($24.1M).
Debt to Equity History and Analysis
Debt Level: BDSX has more cash than its total debt.
Reducing Debt: Insufficient data to determine if BDSX's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BDSX has sufficient cash runway for 6 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: BDSX is forecast to have sufficient cash runway for 5 months based on free cash flow estimates, but has since raised additional capital.
What is Biodesix current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BDSX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BDSX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BDSX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BDSX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as BDSX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Scott Hutton (49 yo)
Mr. Scott Hutton serves as President, Chief Executive Officer and Director at Biodesix, Inc. since January 1, 2020. He served as Chief Operating Officer at Biodesix, Inc. since March 2018 until December 20...
CEO Compensation Analysis
Compensation vs Market: Scott's total compensation ($USD4.65M) is above average for companies of similar size in the US market ($USD771.97K).
Compensation vs Earnings: Scott's compensation has increased whilst the company is unprofitable.
Experienced Management: BDSX's management team is considered experienced (2.3 years average tenure).
Experienced Board: BDSX's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: BDSX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 48.1%.
Biodesix, Inc.'s employee growth, exchange listings and data sources
- Name: Biodesix, Inc.
- Ticker: BDSX
- Exchange: NasdaqGM
- Founded: 2005
- Industry: Health Care Services
- Sector: Healthcare
- Implied Market Cap: US$58.890m
- Shares outstanding: 39.79m
- Website: https://www.biodesix.com
Number of Employees
- Biodesix, Inc.
- 2970 Wilderness Place
- Suite 100
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/21 00:00|
|End of Day Share Price||2022/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.